%0 Journal Article %1 sebastian2025p31834 %A Sebastian, M., %A Nordman, I., %A Ürün, Y., %A Voon, P.J, %A Isla, D., %A Vera, K., %A Orlandi, F., %A Sansar, Bipnesh, %A Winckels, S., %A Mueller, C., %A Triebel, F., %B 2025 World Conference on Lung Cancer %D 2025 %I Springer %J Journal of Thoracic Oncology %K Advanced/Metastatic Chemotherapy Immunotherapy NSCLC %N 10 Suppl.1 %P S559 %R https://doi.org/10.1016/j.jtho.2025.09.1049 %T P3.18.34 TACTI-004, a Phase 3 Trial of Eftilagimod Alfa Plus Pembrolizumab (P) + Chemotherapy (C) vs Placebo + P + C in 1St Line NSCLC %U https://www.sciencedirect.com/science/article/pii/S1556086425020994 %V 20 %X Eftilagimod alfa (E), an antigen presenting cell activator, binds to a subset of MHC class II molecules to mediate T cell (CD4/CD8) recruitment/activation. Prior studies in first line (1L) non-small cell lung cancer (NSCLC) (TACTI-002 NCT03625323: combining E + pembrolizumab (P); INSIGHT-003 NCT03252938 combining E with chemotherapy + P SoC) showed encouraging efficacy results across all PD-L1 strata & excellent safety profiles. TACTI-004 is a double-blinded, randomized, placebo-controlled phase 3 study testing E + SoC vs. placebo + SoC in 1L NSCLC patients (pts). %Z IF - 20.8 (2025)

@article{sebastian2025p31834, abstract = {Eftilagimod alfa (E), an antigen presenting cell activator, binds to a subset of MHC class II molecules to mediate T cell (CD4/CD8) recruitment/activation. Prior studies in first line (1L) non-small cell lung cancer (NSCLC) (TACTI-002 [NCT03625323]: combining E + pembrolizumab (P); INSIGHT-003 [NCT03252938] combining E with chemotherapy + P [SoC]) showed encouraging efficacy results across all PD-L1 strata & excellent safety profiles. TACTI-004 is a double-blinded, randomized, placebo-controlled phase 3 study testing E + SoC vs. placebo + SoC in 1L NSCLC patients (pts).}, added-at = {2026-09-02T13:24:27.000+0200}, annote = {IF - 20.8 (2025)}, author = {{Sebastian, M.} and {Nordman, I.} and {Ürün, Y.} and {Voon, P.J} and {Isla, D.} and {Vera, K.} and {Orlandi, F.} and {Sansar, Bipnesh} and {Winckels, S.} and {Mueller, C.} and {Triebel, F.}}, biburl = {https://www.bibsonomy.org/bibtex/2f732d8ec45607716666300b1be386eef/libraryvaranasi}, booktitle = {2025 World Conference on Lung Cancer}, description = {Scopus, Medline, Science Citation Index Expanded (SCIE), SCImago Journal Rank (SJR), SNIP}, doi = {https://doi.org/10.1016/j.jtho.2025.09.1049}, interhash = {6ecaa217f98596887e5e6e9398b4f200}, intrahash = {f732d8ec45607716666300b1be386eef}, issn = {1556-0864}, journal = {Journal of Thoracic Oncology}, keywords = {Advanced/Metastatic Chemotherapy Immunotherapy NSCLC}, language = {English}, month = {October}, note = {Abstract | First Published on 23 October 2025}, number = {10 Suppl.1}, pages = {S559}, publisher = {Springer}, subjectarea = {Medical Oncology}, timestamp = {2026-09-28T13:08:53.000+0200}, title = {P3.18.34 TACTI-004, a Phase 3 Trial of Eftilagimod Alfa Plus Pembrolizumab (P) + Chemotherapy (C) vs Placebo + P + C in 1St Line NSCLC}, type = {International}, url = {https://www.sciencedirect.com/science/article/pii/S1556086425020994}, volume = 20, year = 2025 }